Samfundsansvar

Nyt omfattende COVID-studie: Naturlige antistoffer 12x mere effektive end vacciner

Morten W. Langer

fredag 27. august 2021 kl. 18:42

Uddrag fra Zerohedge:

The study was described by Bloomberg as “the largest real-world analysis comparing natural immunity – gained from an earlier infection – to the protection provided by one of the most potent vaccines currently in use.” A few days ago, we noted how remarkable it was that the mainstream press was finally giving voice to scientists to criticize President Biden’s push to start doling out booster jabs. Well, this study further questions the credibility of relying on vaccines, given that the study showed that the vaccinated were ultimately 13x as likely to be infected as those who were infected previously, and 27x more likely to be symptomatic.

Alex Berenson, a science journalist who has repeatedly questioned the efficacy of vaccines and masks at preventing COVID, touted the study as enough to “end any debate over vaccines v natural immunity.”

Here’s an excerpt from a report by Science Magazine:

The new analysis relies on the database of Maccabi Healthcare Services, which enrolls about 2.5 million Israelis. The study, led by Tal Patalon and Sivan Gazit at KSM, the system’s research and innovation arm, found in two analyses that people who were vaccinated in January and February were, in June, July, and the first half of August, six to 13 times more likely to get infected than unvaccinated people who were previously infected with the coronavirus. In one analysis, comparing more than 32,000 people in the health system, the risk of developing symptomatic COVID-19 was 27 times higher among the vaccinated, and the risk of hospitalization eight times higher.

This time, the data leave little doubt that natural infection truly is the better option for protection against the delta variant, despite the fact that the US won’t  acknowledge the already infected as having antibodies protecting them from the virus.

As the first country to achieve widepsread coverage by the vaccine, Israel is now in an unthinkable situation: daily case numbers have reached new record levels as the delta variant penetrates the vaccines’ protection like a hot knife slicing through butter.

Source: Bloomberg

At the very least, the results of the study are good news for patients who have already successfully battled COVID but show the challenge of relying exclusively on immunizations to move past the pandemic.

“This analysis demonstrated that natural immunity affords longer lasting and stronger protection against infection, symptomatic disease and hospitalization due to the delta variant,” the researchers said.

Unfortunately, the study also showed that any protection is time-limited. Protection offered by natural infection wanes over time, just like the protection afforded by vaccines: The risk of a vaccine-breakthrough delta case was 13x higher than the risk of developing a second infection when the original illness occurred during January or February 2021. That’s significantly more than the risk for people who were ill earlier in the outbreak.

What’s more, giving a single shot of the vaccine to those who had been previously infected also appeared to boost their protection. Still, the data don’t tell us anything about the long-term benefits of booster doses.

This latest data showing the vaccines don’t offer anywhere near the 90%+ protection that was originally advertised by the FDA after the emergency authorization. Other studies are finding harmful side effects caused by the mRNA jabs are also more prevalent than previously believed.

Read the study pre-print below:

2021.08.24.21262415v1.full by Joseph Adinolfi Jr. on Scribd

Del på facebook
Del på twitter
Del på linkedin
Del på email
Del på print

[postviewcount]

Jobannoncer

Afdelingsleder til nøglerolle inden for økonomistyring i Vejdirektoratet
Wonderful Copenhagen søger en dygtig business controller
Finanstilsynet søger Teamleder til kontor på kapitalmarkedsområdet – prospektområdet
Nysgerrig kollega søges til tilsyn med pengeinstitutter
Pensam søger udviklingsorienteret økonom til product management
Direktør for Job og Økonomi Favrskov Kommune
Dansk Energi søger konsulent til at arbejde med den grønne omstilling
International shipping company seeks ambitious Group Financial Controller
Økonom søges til EjendomDanmark
Plesner søger økonom til Team EU & Competition
Finansiel Stabilitet søger ny kollega til afdelingen Kredit og Interne Advokater
Finansiel Stabilitet søger dygtig og engageret økonom
To dygtige akademikere søges til spændende økonomiopgaver vedrørende de videregående uddannelsesinstitutioner
Senior Financial Controller til Sparekassen Sjælland-Fyn
Socialtilsyn Syd søger en konsulent med stærk økonomisk forståelse
Student til Forhandlingsafdelingen i Dansk Sygeplejeråd
Ergoterapeutforeningen søger teamleder til økonomi
Regnskabschef i Uddannelses- og Forskningsstyrelsen
Ny kollega til stærkt regnskabsteam i Uddannelses- og Forskningsstyrelsen
Nationalbanken søger sektionschef for international økonomi, relationer & strategi
Business analyst til myndighedsrapporterings-teamet
Energinet søger Finansiel Business Partner til Koncernøkonomi
Udviklingsorienteret talknuser til håndtering af driftsbudgetter for det danske el-net
Professionel leder med strategisk overblik og økonomisk indsigt
Kalundborg Kommune søger Teamleder til Team løn, ejendomsskat og opkrævning (LEO)

Mere fra ØU Samfundsansvar

Seneste nyt

Mest læste

Få dit daglige nyhedsoverblik i din indbakke

Seneste rapporter fra eksterne rådgivere

Dybdegående og original 
journalistik siden 1994

Økonomisk Ugebrev har i mere end 25 år leveret indsigtsfuld og dagsordensættende journalistik og analyser til læserne og den brede offentlighed. 

Vi tager ansvar for vores indhold og er tilmeldt:

OM ØU

Log ind

KONTAKT

Telefonisk henvendelse: 70 23 40 10
Telefonerne er åbne alle hverdage fra: 10-15
Salgschef: Sidsel Bogh

Skriv til os på: kontakt@ugebrev.dk.
Vi bestræber os på at besvare henvendelser indenfor 24 timer.

Økonomisk Ugebrev A/S
CVR-nr.: 31760623
Forbindelsesvej 12, 2. tv
2100 København Ø

Log ind

Har du ikke allerede en bruger? Opret dig her.

Analyse af og prognoser for Fixed Income (statsrenter)

Direkte adgang til opdaterede analyser fra toneangivende finanshuse:

Goldman Sachs

Fidelity

Danske Bank

Morgan Stanley

ABN Amro

Jyske Bank

UBS

SEB

Natixis

Handelsbanken

Merril Lynch 

Analyse og prognoser for kort rente, samt for centralbankernes politikker

Links:

RBC

Capital Economics

Yardeni – Central Bank Balance Sheet 

Investing.com: FED Watch Monitor Tool

Nordea

Scotiabank

 

Log ind

[iteras-paywall-login paywallid="qwerty123"]